2487 |
Pharmacologic Agents for Maximal Hyperemia |
Bon-Kwon Koo |
Dec. 12. 13 |
2486 |
Experimental Basis and Clinical Validation of FFR |
Nico Pijls |
Dec. 12. 13 |
2485 |
[Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] No, I Don't |
Seung-Jung Park |
Dec. 11. 13 |
2484 |
[Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] Yes, I Do |
Akiko Maehara |
Dec. 11. 13 |
2483 |
FFR in Acute Coronary Syndrome: Culprit and Non-culprit Lesion |
William F. Fearon |
Dec. 11. 13 |
2482 |
Vulnerable Plaque by OCT |
Takashi Akasaka |
Dec. 11. 13 |
2481 |
Vulnerable Plaque by IVUS or VH-IVUS |
Gary S. Mintz |
Dec. 11. 13 |
2480 |
Can We Predict the Fate of Vulnerable Plaque: Progression or Regression? |
Michael Joner |
Dec. 11. 13 |
2479 |
On the Accuracy and Reproducibility of Physiologic Indices |
Nico Pijls |
Dec. 11. 13 |
2478 |
Edwards Lifesciences: Sapien 3 and Centra System |
Jian (James) Ye |
Aug. 13. 13 |